Why Symptoms Often Lag Behind Treatment Changes

Why this matters

Starting a new medication and not feeling better within days or weeks is a common and frustrating experience when managing a chronic condition. It creates pressure to switch treatment early and can lead to stopping something that was working. Understanding why the lag happens makes it significantly easier to stay the course when it’s right to do so.

Why treatments take time

Medications don’t work like a switch. They shift biological processes gradually. Immunosuppressants, for example, suppress immune activity, but existing activated immune cells persist for days or weeks before naturally dying off. Until they do, inflammation continues even though the medication is working as intended. Beyond that, even after immune activity is suppressed, existing inflammatory chemicals persist in tissues and swelling takes weeks to reduce. Tissue repair is also slow. Healing damaged skin, joints, or gut lining requires cellular regeneration measured in weeks to months.

Most medications also start at a low dose and increase gradually, both to minimise side effects and to find the dose that works for that individual.

Typical timelines

Different treatments have different expected timelines:

• DMARDs such as methotrexate, sulfasalazine, and hydroxychloroquine typically take six to twelve weeks for noticeable improvement and three to six months for full effect
• Biologics can show some improvement within two to four weeks, with the full effect by twelve to sixteen weeks
• Steroids work within hours to days, which is why they’re useful for bridging to slower-acting treatments
• Thyroid replacement takes two to four weeks for initial improvement and six to twelve weeks for full resolution as the dose is optimised

These aren’t delays. They’re the expected pace of how these treatments work biologically.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

What to track while waiting

Symptoms are often the last thing to improve. Before feeling significantly better, other markers may indicate that treatment is working:

• Objective markers. Improving inflammatory markers in blood tests suggest treatment is working even when symptoms persist
• Subtle improvements. Slightly more energy, pain reducing from 8 to 6 out of 10, or fewer new symptoms appearing
• Flare frequency. Even if baseline symptoms persist, flares becoming less frequent or less severe indicate benefit
• Functional gains. Being able to work longer, exercise again, or sleep better all count as meaningful progress, even when symptoms haven’t fully resolved

When to wait versus when to escalate

Waiting longer is generally appropriate when the treatment is still within its expected timeline, objective markers are improving, or subtle gains are occurring. Escalation is warranted when the timeline has been significantly exceeded with no change, symptoms are worsening, objective markers are deteriorating, or side effects are intolerable. Neither waiting indefinitely nor stopping early serves well. The decision should always be made in discussion with the clinical team.

What you could do

• Track symptoms and test results together so that subtle trends become visible over time
• Note functional changes as well as symptom severity. These often improve before symptoms fully resolve
• Attend monitoring appointments as scheduled. Objective results provide reassurance that treatment is being reviewed appropriately
• If the wait feels unmanageable, discuss with the specialist whether a bridging treatment, dose adjustment, or earlier review is appropriate rather than stopping independently

References:

‘A comparison of biological therapies vs traditional immunosuppressant in the management of inflammatory bowel diseases: a narrative review’ (2026) https://doi.org/10.55729/2000-9666.1566

‘Diagnosis and management of rheumatoid arthritis: a review’ (2018) https://doi.org/10.1001/jama.2018.13103

‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update’ (2020) https://doi.org/10.1136/annrheumdis-2019-216655

‘Onset of action of biologics in patients with moderate-to-severe psoriasis’ (2018) https://pubmed.ncbi.nlm.nih.gov/29537442/

‘When is the right time to change therapy? An observational study of the time to response to immunosuppressive drugs in systemic lupus erythematosus’ (2024) https://doi.org/10.1136/lupus-2024-001207

‘2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis’ (2021) https://doi.org/10.1002/acr.24596